Category Archives: Guest Blog

Customer Engagement Isn’t Just About Physicians: It’s About Sales Reps Too

By Karl Tiedemann. Managing the pharma sales force has always been challenging. Reps are spread out geographically, often far from corporate offices, preventing them from taking part in the on-site activities and face-to-face interactions that typically foster a connection to the company. In order to help the sales force achieve their primary goal — educating […]
Also posted in Sales, Strategy | Tagged | 1 Comment

Healthcare Nonprofit Bans Genentech Reps

By Randi Hernandez, Pharmaceutical Technology. After a change in distribution strategy at Genentech, Ascension Health has prohibited sales representatives from the drug maker to solicit physicians at Ascension’s 1900 sites of care around the country. The ban is the result of a supply-chain move that routes three infused cancer medications—Avastin (bevacizumab), Rituxan (rituximab), and Herceptin […]
Also posted in healthcare, Sales | Tagged , , | Leave a comment

Five Measures to Cope with the Side Effects of Health Reform

By Sydney Rubin. With more than 8 million Americans now signed up for health insurance through state health exchanges, The Affordable Care Act (ACA) has begun delivering benefits and new insurance protections to a large swath of Americans, many of whom had no health insurance before. People previously rejected by insurers due to pre-existing conditions […]
Also posted in healthcare, Op-Ed, pricing, Regulatory | Tagged , , , | Leave a comment

US Company Awarded UK's First "Promising Innovative Medicine" Designation

By Leela Barham. The UK’s Medicines and Healthcare Regulatory Authority (MHRA) has awarded Northwest Biotherapeutics, Inc. (Bethesda, MD) the very first “Promising Innovative Medicine”, or PIM designation, for the company’s DCVax-L product.
Also posted in Europe, Global, Regulatory | Tagged , , , | Leave a comment

UK Postpones Decision on Value-Based Assessment — Again

By Leela Barham. Value-based Pricing (VBP) was first discussed as far back as 2007 by the UK’s consumer authority, the now defunct Office of Fair Trading (OFT).  The general concept of VBP was to set almost provisional prices based on the expected value of new medicines using immature data, with provisions to ‘correct’ the price […]
Also posted in Europe, Global, Op-Ed, pricing | Tagged , , , , , , | Leave a comment
  • Categories

  • Meta